Viatris (VTRS) FY2025 10-K Annual Report
Viatris (VTRS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Viatris FY2025 10-K Analysis
Business Overview
- • Global pharma company delivering generics, branded generics, and innovative medicines to ~1B patients across 165+ countries with 30,000+ employees and 27 manufacturing sites
- • Five positive Phase 3 readouts in 2025: meloxicam acute pain, low-dose estrogen patch (FDA action target July 30, 2026), LYNX-2 night driving (MR-142), VEGA-3 presbyopia (MR-141, FDA action H2 2026), and EFFEXOR Japan GAD
- • EWSR launched 2025: up to ~10% global workforce reduction, $700M–$850M in restructuring charges, targeting $600M–$700M in savings once fully implemented
- • 2025 total revenues $14.30B; returned >$1B to shareholders (~$500M buybacks + $561M dividends) despite divestiture headwinds and Indore FDA warning letter impact
- • Acquired Aculys Pharma (Oct 2025) for Japan-exclusive rights to pitolisant (narcolepsy/sleep apnea) and Spydia® Nasal Spray — sharpest pivot yet toward patent-protected innovative assets in Japan
Management Discussion & Analysis
- • Revenue $14.30B, down 3% YoY ($439M decline); Indore facility impact ~$370M drag; Greater China only growth segment, +8% to $2.33B
- • Gross margin 35% vs 38%; adjusted gross margin 56% vs 58%; operating loss $(2.66B) vs near-breakeven $10M in 2024, driven by $2.94B goodwill impairment
- • Best segment: Greater China +8% constant currency; worst: JANZ -11% ($152M decline) from government price cuts and Indore impact
- • Operating cash flow $2.32B (up $13M YoY); capex $378.8M; buybacks $500.5M; dividends $561.2M; 2026 capex guided $350M–$450M
- • 2026 restructuring program targets $600M–$700M savings, $700M–$850M pre-tax charges; Nashik plant fire (Feb 2026) adds supply risk; biosimilar non-compete expiry unlocks new revenue opportunity
Risk Factors
- • FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
- • U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected
- • Top 3 customers ~25% of net sales; limited manufacturing sites plus post-divestiture API supply dependence on single external vendor
- • Inflation Reduction Act (2022) drug price negotiation and most-favored-nation pilot programs risk compressing innovative pipeline product margins
- • Significant indebtedness with refinancing risk at higher rates; $2.94B goodwill impairment charge taken in 2025
Viatris FY2025 Key Financial MetricsXBRL
Revenue
$14.3B
▼ -3.0% YoY
Net Income
-$3.5B
▼ -454.2% YoY
Gross Margin
35.2%
▼ -309bp YoY
Operating Margin
-18.7%
▼ -1876bp YoY
Net Margin
-24.7%
▼ -2035bp YoY
ROE
-23.9%
▼ -2049bp YoY
Total Assets
$37.2B
▼ -10.4% YoY
EPS (Diluted)
$-3.00
▼ -466.0% YoY
Operating Cash Flow
$2.3B
▲ +0.6% YoY
Source: XBRL data from Viatris FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Viatris Annual Reports
Get deeper insights on Viatris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.